Dean J. Welsch

Eradication of Tumors through Simultaneous Ablation of CD276/B7-H3-Positive Tumor Cells and Tumor Vasculature

Steven Seaman, Zhongyu Zhu, Saurabh Saha et al. · Cancer Cell · 2017 · 447 citations

Medicine, Immunology, Oncology +14

First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study

Ryan J. Sullivan, Jeffrey R. Infante, Filip Jankú et al. · Cancer Discovery · 2017 · 418 citations

Medicine, Oncology, Pharmacology +14

Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine

Andrew J. Aguirre, Jonathan A. Nowak, Nicholas D. Camarda et al. · Cancer Discovery · 2018 · 369 citations · Full text

Medicine, Oncology, Dna Repair +10

Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (Ulixertinib)

Ursula A. Germann, Brinley F. Furey, William Markland et al. · Molecular Cancer Therapeutics · 2017 · 234 citations

Medicine, Oncology, Pharmacology +16

Tumor stroma–targeted antibody-drug conjugate triggers localized anticancer drug release

Christopher Szot, Saurabh Saha, Xiaoyan M. Zhang et al. · Journal of Clinical Investigation · 2018 · 125 citations · Full text

Pharmacy, Oncology, Pharmacology +17